Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,199.12
+11.46 (+0.96%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
39
40
Next >
Check Out What Whales Are Doing With REGN
August 25, 2023
Via
Benzinga
Is Regeneron Stock a Buy Now?
August 25, 2023
The company's growth fuel isn't running out yet.
Via
The Motley Fool
Regeneron Announces Investor Conference Presentations
August 23, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Could This Medicine Be the Next Winner for Novartis?
August 23, 2023
The Swiss drugmaker recently reported that a drug candidate met the primary endpoints in phase 3 clinical trials.
Via
The Motley Fool
Top 5 Health Care Stocks That May Fall Off A Cliff
August 23, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Regeneron Awarded $326M Government Contract For COVID-19 Antibody Therapy Development
August 22, 2023
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was awarded a government contract valued at up to $326 million on Tuesday.
Via
Benzinga
Exposures
COVID-19
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
August 22, 2023
Via
Benzinga
18 Analysts Have This to Say About Regeneron Pharmaceuticals
August 16, 2023
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $5,400 Today
August 15, 2023
Via
Benzinga
Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention
August 22, 2023
Program is part of U.S. Government’s ‘Project NextGen’ and provides partial funding for clinical development of a novel monoclonal antibody therapy
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron's Crucial Eylea HD Approval: A Shield Against Potential Biosimilar Competition?
August 21, 2023
Friday, the FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration, diabetic macular edema,
Via
Benzinga
Exposures
Product Safety
Value Stocks Outshine Growth Amidst Rising Treasury Yields: Key Sectors and Stocks Analyzed
August 21, 2023
The Vanguard Value Index Fund ETF (ARCA: VTV) has beaten the Vanguard Growth Index Fund ETF (ARCA: VUG) by 5% during the past month. The momentum shift comes as investors recalibrate their strategies...
Via
Benzinga
Topics
ETFs
This Is What Whales Are Betting On Regeneron Pharmaceuticals
August 14, 2023
Via
Benzinga
Why the quality investor may take a look at NASDAQ:REGN.
August 11, 2023
REGENERON PHARMACEUTICALS (NASDAQ:REGN) may be suited for quality investing, we'll explore why in this article.
Via
Chartmill
Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner
August 21, 2023
Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years.
Via
Talk Markets
FDA Approves Regeneron's Drug For Ultra Rare Immune Disorder
August 21, 2023
The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Veopoz (pozelimab-bbfg) for adult and pediatric patients one year of age and older with CHAPLE disease, known as CD55-deficient
Via
Benzinga
Exposures
Product Safety
Why This Regeneron Approval 'Could Not Come Soon Enough' As Novartis Looms
August 21, 2023
The FDA signed off on Regeneron's high-dose Eylea about two months earlier than expected.
Via
Investor's Business Daily
Exposures
Product Safety
FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness
August 21, 2023
The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration (wAMD), diabetic macular edema (DME),
Via
Benzinga
Exposures
Product Safety
Is Regeneron Pharmaceuticals Still a Top Growth Stock?
August 21, 2023
The biotech's focus on innovation could be a boon for shareholders.
Via
The Motley Fool
This Is What Whales Are Betting On Regeneron Pharmaceuticals
August 10, 2023
Via
Benzinga
EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
August 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease
August 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
August 17, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
3 Strong Biotech Performers To Watch As Sector Nears Breakout
August 17, 2023
As the IBB ETF nears a potential breakout, watch for strong performers like Regeneron Pharmaceuticals, Vertex, and Exelixis to continue outperforming.
Via
MarketBeat
Topics
ETFs
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ElectraMeccanica (Nasdaq - SOLO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq - DBTX)
August 15, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales
August 14, 2023
The company is working on a treatment for stomach diseases ulcerative colitis and Crohn's disease.
Via
Investor's Business Daily
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
August 11, 2023
Investors are on the hunt for undervalued, underfollowed and emerging stocks, and retail traders have countless methods at their disposal to uncover new information. For some, this may be...
Via
Benzinga
The 7 Best Value Stocks to Buy in August
August 10, 2023
Stop chasing the hot flavors of the week and instead be friendly to your wallet with these ideas for best value stocks to buy.
Via
InvestorPlace
Regeneron's Aflibercept 8mg Shows Sustained Vision Gains At Two Years
August 10, 2023
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced two-year (96 weeks) topline data from the pivotal PULSAR trial investigating aflibercept 8 mg in patients with wet age-related
Via
Benzinga
Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration
August 10, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
39
40
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.